

## GCP Inspections Registry at EDA

| SN | Study Code<br>(Specified as per<br>the submitted<br>protocol) | Sponsor/CRO                                                                                                                                                                                                                        | Intervention(s)<br>“Used IMPs & its<br>type (Biological,<br>Pharmaceutical,<br>Innovative,<br>Herbal, or medical<br>device) | Study<br>Phase<br>(I, II,<br>III, or<br>IV) | Inspected<br>site(s)/related<br>entities                                 | Country:<br>-Inside<br>Egypt<br>-Outside<br>Egypt | Inspection<br>date | Regulatory<br>decision:<br>-Comply<br>-Suspended<br>-Terminated |
|----|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------|--------------------|-----------------------------------------------------------------|
| 1. | CLEE011A3201C                                                 | <b>Sponsor:</b> Novartis<br><b>CRO:</b> MCT                                                                                                                                                                                        | Ribociclib<br><b>(Pharmaceutical)</b>                                                                                       | Phase II                                    | Nasser Institute,<br>Cairo                                               | Inside Egypt                                      | 31/1/2022          | Comply                                                          |
| 2. | GBT440-032                                                    | <b>Sponsor:</b> GBT<br>(Subsidiary of<br>Pfizer)<br><b>CRO:</b> CTI                                                                                                                                                                | Voxelotor<br><b>(Pharmaceutical)</b>                                                                                        | Phase<br>III                                | Ain Shams<br>University,<br>Faculty of<br>Medicine CRC<br>(MASRI), Cairo | Inside Egypt                                      | 1/2/2022           | Comply                                                          |
| 3. | SPHINX221220<br>20                                            | Sponsor: Eva<br>Pharma &<br>Veterinary Serum<br>& Vaccine<br>Research Institute<br>(VSVRI) & The<br>Supreme Council of<br>University<br>Hospitals &<br>Ministry of Higher<br>Education and<br>Scientific Research<br>CRO: Dataclin | EgyVax Vaccine<br><b>(Biological)</b>                                                                                       | Phase I                                     | Al-Manial<br>Specialized<br>Hospital,Cairo<br>university<br>hospitals    | Inside Egypt                                      | 20/2/2022          | Comply                                                          |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|    |                       |                                                                                                                                                                                  |                                                                                                            |               |                                                                        |              |            |        |
|----|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------|------------------------------------------------------------------------|--------------|------------|--------|
| 4. | 01-sputnik light-2021 | Sponsor: Human Vaccine LLC<br>CRO: PDC                                                                                                                                           | Sputnik-Light: vector vaccine against the SARS-CoV-2 -induced coronavirus infection<br><b>(Biological)</b> | Phase III     | Katameya Medical Center<br>Cairo                                       | Inside Egypt | 6/3/2022   | Comply |
| 5. | MN39159               | Sponsor: Roche<br>CRO: IQIVIA                                                                                                                                                    | Ocrelizumab<br><b>(Biological)</b>                                                                         | Phase III     | CRC (MASRI), faculty of medicine, Ain Shams university hospital, Cairo | Inside Egypt | 22/3/2022  | Comply |
| 6. | APD334-202            | <b>Sponsor:</b> Arena Pharmaceuticals (Subsidiary of Pfizer)<br><b>CRO:</b> IQVIA                                                                                                | Etrasimod<br><b>(Pharmaceutical)</b>                                                                       | Phase II/ III | Theodor Bilharz Research Institute, Cairo                              | Inside Egypt | 23/3/ 2022 | Comply |
| 7. | SPHINX221220 20       | Sponsor: Eva Pharma & Veterinary Serum & Vaccine Research Institute (VSVRI) & The Supreme Council of University Hospitals & Ministry of Higher Education and Scientific Research | EgyVax Vaccine<br><b>(Biological)</b>                                                                      | Phase I       | Al-Manial Specialized Hospital, Cairo                                  | Inside Egypt | 10/4/2022  | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                          | CRO: Dataclin                                                         |                                               |              |                                                                                                            |              |                        |            |
|-----|--------------------------|-----------------------------------------------------------------------|-----------------------------------------------|--------------|------------------------------------------------------------------------------------------------------------|--------------|------------------------|------------|
| 8.  | GBT440-034               | <b>Sponsor:</b><br>GBT (Subsidiary of<br>Pfizer)<br><b>CRO:</b> IQVIA | Voxelotor<br><b>(Pharmaceutical)</b>          | Phase<br>III | Cairo University,<br>Abu El Rich<br>Hospital,<br>Department of<br>Pediatrics, Cairo.                       | Inside Egypt | 13/4/2022              | Comply     |
| 9.  | BO40336                  | <b>Sponsor:</b> Roche<br><b>CRO:</b> NA                               | Adjuvant Alectinib<br><b>(Pharmaceutical)</b> | Phase<br>III | Cairo University,<br>Kasr Al Eini,<br>Center of<br>Radiation<br>Oncology and<br>Nuclear Medicine,<br>Cairo | Inside Egypt | 30/5/2022              | Comply     |
| 10. | EMERALD-2                | Sponsor:<br>AstraZeneca<br><b>CRO:</b> IQVIA                          | Durvalumab<br><b>(Biological)</b>             | Phase<br>III | National liver<br>institute, Menoufia                                                                      | Inside Egypt | 7/6/2022               | Comply     |
| 11. | MK4482-013<br>MOVE-Ahead | <b>Sponsor:</b> MSD<br><b>CRO:</b> NA                                 | Molnupiravir<br><b>(Pharmaceutical)</b>       | Phase<br>III | National<br>Hepatology and<br>Tropical Medicine<br>Research Institute<br>(NHTMRI), Cairo                   | Inside Egypt | 13/6/2022              | Comply     |
| 12. | EMERALD-2                | Sponsor:<br>AstraZeneca<br><b>CRO:</b> IQVIA                          | Durvalumab<br><b>(Biological)</b>             | Phase<br>III | National<br>hepatology and<br>tropical medicine<br>institute<br>(NHTMRI), Cairo                            | Inside Egypt | 17/8/2022              | Comply     |
| 13. | SPHINX221220<br>20       | Sponsor: Eva<br>Pharma &                                              | EgyVax Vaccine<br><b>(Biological)</b>         | Phase I      | Al-Manial<br>Specialized                                                                                   | Inside Egypt | 24/8/2022<br>25/8/2022 | Suspension |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                       |                                                                                                                                                                                 |                                                                                                            |           |                                                            |              |           |                                                |
|-----|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|-----------|------------------------------------------------------------|--------------|-----------|------------------------------------------------|
|     |                       | Veterinary Serum & Vaccine Research Institute (VSVRI) & The Supreme Council of University Hospitals & Ministry of Higher Education and Scientific Research<br><br>CRO: Dataclin |                                                                                                            |           | Hospital and My lab, Cairo                                 |              |           | Resumed                                        |
| 14. | 01-sputnik light-2021 | Sponsor: Human Vaccine LLC<br>CRO: PDC                                                                                                                                          | Sputnik-Light: vector vaccine against the SARS-CoV-2 -induced coronavirus infection<br><b>(Biological)</b> | Phase III | Katameya Medical Center, Cairo                             | Inside Egypt | 29/8/2022 | Comply                                         |
| 15. | EMERALD-2             | Sponsor: AstraZeneca<br>CRO: IQIVIA                                                                                                                                             | Durvalumab<br><b>(Biological)</b>                                                                          | Phase III | Alexandria University , CRC, Alexandria                    | Inside Egypt | 14/9/2022 | Comply                                         |
| 16. | GBT440-032            | <b>Sponsor:</b> GBT (Subsidiary of Pfizer)<br><b>CRO:</b> CTI                                                                                                                   | Voxelotor<br><b>(Pharmaceutical)</b>                                                                       | Phase III | Alexandria University Faculty of Medicine, CRC, Alexandria | Inside Egypt | 15/9/2022 | Suspension (21/9/2022)<br>Resuming (29/9/2023) |
| 17. | F901318/0032          | <b>Sponsor:</b> F2G<br><b>CRO:</b> IQVIA                                                                                                                                        | Olorofim<br><b>(Pharmaceutical)</b>                                                                        | Phase IIb | Ain Shams University, Faculty of                           | Inside Egypt | 19/9/2022 | Comply                                         |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                          |                                                                |                                                   |                       | Medicine CRC<br>(MASRI), Cairo                                                          |              |            |        |
|-----|--------------------------|----------------------------------------------------------------|---------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------|--------------|------------|--------|
| 18. | MD-004 (EZVent)          | Sponsor : EZZ medical industries<br>CRO : Dataclin             | EZVent ventilator system<br>(Medical device)      | Pivotal/<br>Phase III | Critical Care Centre, Kasr Al Einy, Cairo University Hospital, Cairo                    | Inside Egypt | 13/10/2022 | Comply |
| 19. | MK4482-002               | <b>Sponsor:</b> MSD<br><b>CRO:</b> NA                          | Molnupiravir<br>(Pharmaceutical)                  | Phase II/<br>III      | Abbasya Fever Hospital, Cairo.                                                          | Inside Egypt | 19/10/2022 | Comply |
| 20. | M16-067                  | Sponsor: Abbvie<br>CRO: NA                                     | Risankizumab<br>(Biological)                      | Phase IIb/ III        | AIR force specialized hospital, Cairo                                                   | Inside Egypt | 25/10/2022 | Comply |
| 21. | CLSYN.1702               | <b>Sponsor:</b> Hamilton Health Science<br><b>CRO:</b> Clinmax | Colchicine and Spironolactone<br>(Pharmaceutical) | Phase III/ IV         | Fayoum General Hospital, Fayoum.                                                        | Inside Egypt | 8/11/2022  | Comply |
| 22. | MK4482-013<br>MOVE-Ahead | <b>Sponsor:</b> MSD<br><b>CRO:</b> NA                          | Molnupiravir<br>(Pharmaceutical)                  | Phase III             | Imbaba Fever Hospital, Cairo.                                                           | Inside Egypt | 16/11/2022 | Comply |
| 23. | CLSYN.1702               | <b>Sponsor:</b> Hamilton Health Science<br><b>CRO:</b> Clinmax | Colchicine and Spironolactone<br>(Pharmaceutical) | Phase III/ IV         | Suez Canal University Hospital, Faculty of Medicine, Cardiology Department, Suez Canal. | Inside Egypt | 6/12/2022  | Comply |
| 24. | CAIN457A2310             | Sponsor: Novartis<br>CRO: MCT                                  | Secukinumab<br>(Biological)                       | Phase III             | CRC (MASRI), faculty of medicine, Ain Shams university                                  | Inside Egypt | 17/1/2023  | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                                       |                                                                                                                                                                                                                                        |                                |             | Cairo                                                                                                                                       |              |           |        |
|-----|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------|--------|
| 25. | SPHINX221220<br>20                    | Sponsor: Eva<br>Pharma &<br>Veterinary Serum<br>& Vaccine<br>Research Institute<br>(VSVRI) & The<br>Supreme Council of<br>University<br>Hospitals &<br>Ministry of Higher<br>Education and<br>Scientific Research<br><br>CRO: Dataclin | EgyVax Vaccine<br>(Biological) | Phase I     | Al-Manial<br>Specialized<br>Hospital, Cairo                                                                                                 | Inside Egypt | 1/2/2023  | Comply |
| 26. | Cl_Tr_1712201<br>9<br>MIRACLE-<br>ALA | <b>Sponsor:</b> EVA<br>Pharma<br><b>CRO:</b> MARC                                                                                                                                                                                      | Thiotacid<br>(Pharmaceutical)  | Phase<br>IV | Alexandria<br>University<br>Hospital, Diabetes,<br>Metabolism, and<br>Lipidology Unit,<br>Department of<br>Internal Medicine,<br>Alexandria | Inside Egypt | 2/3/2023  | Comply |
| 27. | ENRICH-AF                             | <b>Sponsor:</b> Hamilton<br>Health Science<br><b>CRO:</b> Clinmax                                                                                                                                                                      | Edoxaban<br>(Pharmaceutical)   | Phase<br>IV | Zagazig<br>University<br>Hospital,<br>Department of<br>Neurology,<br>Zagazig                                                                | Inside Egypt | 30/3/2023 | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                    |                                                                                           |                                                                         |                  |                                                                                           |              |           |        |
|-----|--------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------|--------------|-----------|--------|
| 28. | APD334-202         | <b>Sponsor:</b> Arena<br>Pharmaceutical<br>(Subsidiary of<br>Pfizer)<br><b>CRO:</b> IQVIA | Etrasimod<br>( <b>Pharmaceutical</b> )                                  | Phase II/<br>III | Ain Shams<br>University,<br>Faculty of<br>Medicine CRC<br>(MASRI), Cairo.                 | Inside Egypt | 21/5/2023 | Comply |
| 29. | CLEE011A3201C      | <b>Sponsor:</b> Novartis<br><b>CRO:</b> MCT                                               | Ribociclib<br>( <b>Pharmaceutical</b> )                                 | Phase II         | Baheya<br>Foundation for<br>Early Detection &<br>Treatment of<br>Breast Cancer,<br>Cairo. | Inside Egypt | 24/5/2023 | Comply |
| 30. | M16-066            | Sponsor: Abbvie<br>CRO: NA                                                                | Risankizumab<br>( <b>Biological</b> )                                   | Phase<br>III     | National Liver<br>Institute,<br>Menoufia<br>University,<br>Menoufia                       | Inside Egypt | 30/5/2023 | Comply |
| 31. | Cl_Tr_1712201<br>9 | <b>Sponsor:</b> EVA<br>Pharma<br><b>CRO:</b> MARC                                         | Thiotacid<br>( <b>pharmaceutical</b> )                                  | Phase<br>IV      | Mansoura<br>University,<br>Intrinsic<br>Specialized<br>Hospital,<br>Mansoura.             | Inside Egypt | 7/6/2023  | Comply |
| 32. | COAV101B123<br>01  | Sponsor: Novartis<br>CRO: MCT                                                             | Zolgensma<br>(Onasemnogene<br>abeparvovec)<br><br>( <b>Innovative</b> ) | Phase<br>III     | Department of<br>Neurology, Ain<br>Shams University<br>Specialized<br>Hospital, Cairo     | Inside Egypt | 20/6/2023 | Comply |
| 33. | GBT2104-131        | Sponsor: Global<br>Blood Therapeutics                                                     | Inclacumab<br>( <b>Biological</b> )                                     | Phase<br>III     | Clinical Research<br>Center, Faculty of                                                   | Inside Egypt | 19/7/2023 | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                     |                                                               |                                                                                          |                             |                                                                                                  |                  |           |                           |
|-----|---------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------|------------------|-----------|---------------------------|
|     |                     | /Pfizer<br>CRO: MCT                                           |                                                                                          |                             | Medicine, Cairo<br>University hospital<br>& Abo El Rish<br>Hospital                              |                  |           |                           |
| 34. | GO42784<br>LidERA   | <b>Sponsor:</b> Roche<br><b>CRO:</b> MCT                      | Giredestrant<br>( <b>Pharmaceutical</b> )                                                | Phase<br>III                | Dar El Salam<br>Cancer Hospital,<br>Cairo.                                                       | Inside Egypt     | 30/7/2023 | Comply                    |
| 35. | MP-ADA1-01          | Sponsor:<br>Minapharm                                         | Adessia<br>( <b>Biological</b> )                                                         | Phase I                     | CRS Berlin<br>GmbH, Germany                                                                      | Outside<br>Egypt | 31/7/2023 | Comply                    |
| 36. | MP-ADA1-01          | Sponsor:<br>Minapharm                                         | Adessia<br>( <b>Biological</b> )                                                         | Phase I                     | CRS Mannheim<br>GmbH, Germany                                                                    | Outside<br>Egypt | 3/8/2023  | Comply                    |
| 37. | MP-ADA1-01          | Sponsor:<br>Minapharm                                         | Bonosome<br>( <b>Biological</b> )                                                        | Phase I                     | CRS Mannheim<br>GmbH, Germany                                                                    | Outside<br>Egypt | 4/8/2023  | Comply                    |
| 38. | CIPRO-001           | <b>Sponsor:</b><br>Minapharm,<br><b>CRO:</b><br>Nagy Research | Cipro Diazole ®<br>Tablets<br>(Ciprofolxacin/Me<br>tronidazole)<br>( <b>Innovative</b> ) | Phase<br>III                | General Syrgery<br>department,<br>Menoufia<br>University<br>Hospital,<br>Menoufia                | Inside Egypt     | 16/8/2023 | Suspension<br>(12/9/2022) |
| 39. | CEGA230B240<br>4    | <b>Sponsor:</b> Novartis<br><b>CRO:</b> MCT                   | Triclabendazole<br>(EGATEN)<br>( <b>Pharmaceutical</b> )                                 | Phase<br>IV                 | Al Mounira<br>Children Hospital,<br>Pediatric<br>Hepatology Unit,<br>Cairo University,<br>Cairo. | Inside Egypt     | 28/8/2023 | Comply                    |
| 40. | MD-004 (<br>EZVent) | Sponsor : EZZ<br>medical industries<br>CRO : Dataclin         | EZVent ventilator<br>system<br>( <b>Medical device</b> )                                 | Pivotal<br>confirm<br>atory | Critical Care Unit,<br>Kasr Al Eini<br>Hospital, Cairo                                           | Inside Egypt     | 4/9/2023  | Comply                    |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |            |                                                                       |                                                                 | phase<br>(III) | University, Cairo.                                                                                   |              |                        |        |
|-----|------------|-----------------------------------------------------------------------|-----------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------------|--------------|------------------------|--------|
| 41. | URSO - 003 | <b>Sponsor:</b><br>Minapharm,<br><b>CRO:</b><br>Nagy Research         | Ursoplus®<br>capsules/<br>Ursofalk®<br>capsules<br>(Innovative) | Phase<br>IV    | Department of<br>Endemic Diseases<br>Medicine, Helwan<br>University<br>Hospital, Badr<br>City, Cairo | Inside Egypt | 14/9/2023              | Comply |
| 42. | ENRICH-AF  | <b>Sponsor:</b> Hamilton<br>Health Science<br><b>CRO:</b> Clinmax     | Edoxaban<br>(Pharmaceutical)                                    | Phase<br>IV    | Fayoum General<br>Hospital, Fayoum.                                                                  | Inside Egypt | 30/9/2023              | Comply |
| 43. | M16-000    | Sponsor: Abbvie<br>CRO: NA                                            | Risankizumab<br>(Biological)                                    | Phase<br>III   | CRC Alexandria<br>University<br>Hospital,<br>Alexandria.                                             | Inside Egypt | 2/10/2023              | Comply |
| 44. | MN39159    | Sponsor: Roche<br>CRO: IQIVIA                                         | Ocrelizumab<br>(Biological)                                     | Phase<br>III   | CRC Alexandria<br>University<br>Hospital,<br>Alexandria.                                             | Inside Egypt | 3/10/2023              | Comply |
| 45. | GBT440-034 | <b>Sponsor:</b> GBT<br>(Subsidiary of<br>Pfizer)<br><b>CRO:</b> IQVIA | Voxelotor<br>(Pharmaceutical)                                   | Phase<br>III   | Zagazig<br>University<br>Hospital,<br>Department of<br>Pediatrics,<br>Zagazig.                       | Inside Egypt | 5/11/2023              | Comply |
| 46. | M14-430    | <b>Sponsor:</b> Abbvie<br><b>CRO:</b> NA                              | Upadacitinib<br>(ABT-494)<br>(Pharmaceutical)                   | Phase<br>III   | National Liver<br>Institute-Menoufia<br>University,                                                  | Inside Egypt | 6/12/2023<br>7/12/2023 | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                    |                                                                     |                                                                   |                                         |                                                                                        |              |            |                                                       |
|-----|--------------------|---------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------|--------------|------------|-------------------------------------------------------|
|     |                    |                                                                     |                                                                   |                                         | Menoufia.                                                                              |              |            |                                                       |
| 47. | COAV101B123<br>01  | Sponsor: Novartis<br>CRO: MCT                                       | Zolgensma<br>(Onasemnogene<br>abeparvovec)<br><b>(Innovative)</b> | Phase<br>III                            | Department of<br>Neurology, Ain<br>Shams University<br>Specialized<br>Hospital.        | Inside Egypt | 13/12/2023 | Comply                                                |
| 48. | CERE-CAP           | investigator-<br>initiated                                          | Cerebrolysin<br><b>(Biological)</b>                               | Phase<br>III                            | Neurology<br>department, Ain<br>Shams Hospital,<br>Cairo.                              | Inside Egypt | 26/12/2023 | Termination<br>(15/1/2024)                            |
| 49. | GBT440-032         | <b>Sponsor:</b> GBT<br>(Subsidiary of<br>Pfizer)<br><b>CRO:</b> CTI | Voxelotor<br><b>(Pharmaceutical)</b>                              | Phase<br>III                            | Al Mounira<br>Children Hospital,<br>Cairo University,<br>Cairo.                        | Inside Egypt | 28/12/2023 | Comply                                                |
| 50. | MD-004 (EZVent)    | <b>Sponsor:</b> EZZ<br>medical industries<br><b>CRO:</b> Dataclin   | EZVent ventilator<br>system<br><b>(Medical device)</b>            | Pivotal confirm<br>atory phase<br>(III) | Critical Care Unit,<br>Kasr Al Eini<br>Hospital, Cairo<br>University, Cairo.           | Inside Egypt | 2/1/2024   | Suspension<br>(1/1/2024)<br>Resumption<br>(13/1/2024) |
| 51. | CLSYN.1702         | <b>Sponsor:</b> Hamilton<br>Health Science<br><b>CRO:</b> Clinmax   | Colchicine &<br>Spironolactone<br><b>(Pharmaceutical)</b>         | Phase<br>III/ IV                        | National Heart<br>Institute, Cairo.                                                    | Inside Egypt | 7/2/2024   | Comply                                                |
| 52. | Cl_Tr_1712201<br>9 | <b>Sponsor:</b> EVA<br>Pharma<br><b>CRO:</b> MARC                   | Thiotacid<br><b>(pharmaceutical)</b>                              | Phase<br>IV                             | Beni-Suef<br>University<br>Hospital, Diabetes<br>and Endocrinology<br>Unit, Beni-Suef. | Inside Egypt | 5/3/2024   | Comply                                                |
| 53. | EMERALD-2          | <b>Sponsor:</b>                                                     | Durvalumab                                                        | Phase                                   | Clinical Oncology                                                                      | Inside       | 7/3/2024   | Comply                                                |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |              |                                                                                 |                                                                       |                          |                                                                |              |           |            |
|-----|--------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------|----------------------------------------------------------------|--------------|-----------|------------|
|     |              | AstraZeneca<br>CRO: IQVIA                                                       | (Biological)                                                          | III                      | dep., Faculty of<br>medicine, Assiut<br>university<br>Hospital | Egypt        |           |            |
| 54. | GO42784      | Sponsor: Roche<br>CRO: MCT                                                      | Giredestrant<br>(Pharmaceutical)                                      | Phase<br>III             | Sohag Oncology<br>Center                                       | Inside Egypt | 4/4/2024  | Compliance |
| 55. | GBT2104-131  | Sponsor:<br>GBT/Pfizer<br>CRO: MCT                                              | Inclacumab<br>(Biological)                                            | Phase<br>III             | MASRI CRC, Ain<br>Shams University                             | Inside Egypt | 8/5/2024  | Comply     |
| 56. | APD334-202   | Sponsor: Arena<br>Pharmaceutical (a<br>wholly owned<br>subsidiary of<br>Pfizer) | Etrasimod<br>(Pharmaceutical)                                         | Phase<br>III             | Egyptian Liver<br>Research Institute<br>and Hospital           | Inside Egypt | 23/5/2024 | Compliance |
| 57. | GBT440-038   | Sponsor: GBT (a<br>wholly owned<br>subsidiary of<br>Pfizer)                     | Voxelotor<br>(Pharmaceutical)                                         | Phase<br>III             | Alexandria<br>University,<br>Faculty of<br>Medicine CRC        | Inside Egypt | 27/6/2024 | Compliance |
| 58. | MO42541      | sponsor: Roche                                                                  | Atezolizumab<br>With Lenvatinib or<br>Sorafenib<br>(Biological)       | Phase<br>III             | Air Force<br>Specialized<br>Hospital                           | Inside Egypt | 30/7/2024 | Comply     |
| 59  | MOO-B-24-223 | Apex Pharma S.A.E<br>Badr City, Egypt                                           | Moodapex 100 mg<br>Film Coated Tablets<br>(Pharmaceutical)            | Phase I<br>(BE<br>Study) | Future Research<br>Center.                                     | Inside Egypt | 5/8/2024  | Comply     |
| 60  | PEACE-180910 | Sponsors:<br>-The Nile Co. For<br>Pharmaceuticals<br>and Chemical               | ATP Containing<br>Parenteral vitamin-B<br>Complex<br>(Pharmaceutical) | Phase<br>IV              | National Institute of<br>Diabetes and<br>Endocrinology         | Inside Egypt | 7/8/2024  | Comply     |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|     |                                             |                                                                                                                                              |                                                                                  |                    |                                               |              |           |        |
|-----|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------|-----------------------------------------------|--------------|-----------|--------|
|     |                                             | Industries (Nile Pharma) & -Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)& -SEDICO Pharmaceuticals Company CRO: Dataclin |                                                                                  |                    |                                               |              |           |        |
| 61  | Zi-Pan/MUP-1023-71                          | Medical Union Pharmaceuticals                                                                                                                | Pantoloc 40 mg Enteric Coated Tablets (Pharmaceutical)                           | Phase I (BE Study) | Zi Diligence Site-1                           | Inside Egypt | 13/8/2024 | Comply |
| 62  | P-0524/145                                  | Ecco Pharm                                                                                                                                   | Ezedoic 180/10 mg Film Coated Tablets (Pharmaceutical)                           | Phase I (BE Study) | Egyptian Research and Development Company     | Inside Egypt | 20/8/2024 | Comply |
| 63  | PHG-NAM/EMP-0724/20 and PHG-NAM/EMP-0724/21 | Namaa Egypt for Medical Pharmaceutical Industries                                                                                            | Nemcoglifzin 25 mg Film Coated Tablet & Empagradplanet 25mg FCT (Pharmaceutical) | Phase I (BE Study) | Pharmaguide BE Center                         | Inside Egypt | 3/9/2024  | Comply |
| 64  | CEGA230B240 4                               | Novartis                                                                                                                                     | EGATEN™ (Pharmaceutical)                                                         | Phase IV           | Alexandria University Faculty of Medicine CRC | Inside Egypt | 5/9/2024  | Comply |
| 65. | MOM-M281-006                                | Sponsor: Janssen CRO: MCT                                                                                                                    | M281 ( Biological)                                                               | Phase II/III       | National Cancer Institute                     | Inside Egypt | 5/9/2024  | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |

|    |                         |                                                                |                                                          |                    |                                                     |              |           |        |
|----|-------------------------|----------------------------------------------------------------|----------------------------------------------------------|--------------------|-----------------------------------------------------|--------------|-----------|--------|
| 66 | NERP-NER-B-12-23/608    | Nerhadou International for Pharmaceuticals and Nutraceuticals  | Nerphrenia 5 mg Oro-dispersible film (Pharmaceutical)    | Phase I (BE Study) | Pharmasolutions BE Center                           | Inside Egypt | 10/9/2024 | Comply |
| 67 | PRO-07-24-EMP (14)      | Eva Pharma, Egypt                                              | Mellitofix 25 mg Film Coated Tablets (Pharmaceutical)    | Phase I (BE Study) | MARC BE Center                                      | Inside Egypt | 16/9/2024 | Comply |
| 68 | D910VC00001 "EMERALD-3" | AstraZeneca                                                    | Durvalumab in combination with Tremelimumab (Biological) | Phase III          | ELRIAH<br>Egyptian Research and Development Company | Inside Egypt | 17/9/2024 | Comply |
| 69 | BES-381                 | Alexandria Company for Pharmaceuticals and Chemical Industries | Pental 400 mg sustained release tablets (Pharmaceutical) | Phase I (BE Study) | ICBR Center                                         | Inside Egypt | 23/9/2024 | Comply |

|           |        |                |
|-----------|--------|----------------|
| Color     | Green  | Biological     |
| Indicator | Blue   | Pharmaceutical |
|           | Orange | Medical Device |
|           | Gray   | Innovative     |
|           | Red    | Herbal         |